3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lymphoma, T-Cell, Peripheral
5
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, T-Cell
3
Lymphoma
2
Immunoblastic Lymphadenopathy
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Mycosis Fungoides
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Prolymphocytic, T-Cell
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Doxorubicin
6
Specimen Handling
5
Radiotherapy
3
Radiation
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Biopsy
3
pembrolizumab
2
liposomal doxorubicin
2
eribulin
2
Ifosfamide
2
toripalimab
1
talimogene laherparepvec
1
rucaparib
1
ribociclib
1
regorafenib
1
peposertib
1
pazopanib
1
olaratumab
1
olaparib
1
lenvatinib
1
futibatinib
1
durvalumab
1
dinutuximab
1
cemiplimab
1
cediranib
1
cabozantinib
1
avelumab
1
anlotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Leiomyosarcoma
×
romidepsin
×
1 year
×
Clear all
No trials found.